PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic...

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Programmed cell death ligand 1 (PD-L1) is a key immune checkpoint molecule expressed on tumor cells and in the tumor microenvironment.
• PD-L1 expression is observed in various human malignancies, including a subset of aggressive lymphomas.
• EBV-negative diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoid malignancy with diverse clinical and pathological features.

Purpose of the Study:

• To investigate the clinical and pathological characteristics of EBV-negative DLBCL cases expressing PD-L1.
• To evaluate the prognostic significance of PD-L1 expression in DLBCL patients treated with standard chemotherapy.
• To determine if PD-L1 expression can identify patients who may benefit from targeted immunotherapy.

Main Methods:

• Immunohistochemical staining for PD-L1 was performed on 86 DLBCL tumor samples.
• Clinical data, including treatment response and survival, were collected and analyzed.
• Statistical analyses, including age/sex-adjusted and multivariate models, were used to assess prognostic factors.

Main Results:

• 16% of EBV-negative DLBCL cases (14/86) showed positive PD-L1 expression on tumor cells.
• PD-L1 positive cases exhibited a higher frequency of non-germinal center B-cell (non-GCB) type and advanced Ann Arbor stage (II-IV).
• PD-L1 expression was an independent predictor of inferior overall survival (OS), despite no significant differences in remission or progression-free survival.

Conclusions:

• PD-L1 expression in EBV-negative DLBCL is associated with unfavorable clinicopathological features and poorer long-term survival.
• PD-L1 status can serve as an independent prognostic marker in DLBCL.
• Identifying PD-L1 positive DLBCL patients may facilitate the selection of individuals for immunotherapy interventions.